(INTREPID-1) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Dexamethasone (Primary) ; Oprozomib (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms INTREPID-1
- Sponsors Amgen
- 13 Feb 2017 Planned number of patients changed from 38 to 64.
- 13 Feb 2017 Status changed from not yet recruiting to recruiting.
- 24 Jan 2017 Planned initiation date changed from 1 Dec 2016 to 1 Feb 2017.